Higher nasal carriage rate of methicillin-resistant Staphylococcus aureus among dental students who have clinical experience

The Journal of the American Dental Association
Yoo Sang BaekYeon-Jee Yoo

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) has been isolated from dental clinical surfaces, dental patients, and dental health care professionals. The authors conducted a study to determine the prevalence rate of nasal MRSA colonization among dental school students and to identify the characteristics of the isolated strains. The authors collected nasal samples from 159 dental students. The authors performed mecA gene detection, staphylococcal cassette chromosome mec (SCCmec) typing, and antimicrobial susceptibility tests on each sample. The authors compared the results of 2 groups (students who had clinical experience and students who did not have clinical experience). Five (3.1%) dental students had MRSA colonization, as confirmed by the presence of the mecA gene in the nasal cavity. Prior clinical experience was associated significantly with nasal MRSA carriage (P < .05). Four of the strains were SCCmec type IV, and 1 strain was SCCmec type I. All isolates were resistant to amoxicillin and clavulanic acid, imipenem, and oxacillin, but were susceptible to several antimicrobial agents including mupirocin, trimethoprim and sulfamethoxazole, and rifampin. The nasal MRSA colonization was eradicated with the use of mupiroci...Continue Reading

References

Jun 1, 1992·Critical Care Medicine·F A ScannapiecoJ M Mylotte
Jan 19, 1991·British Dental Journal·M V Martin, P Hardy
Jan 1, 1995·Journal of Endodontics·N HoribaH Nakamura
Aug 5, 2000·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·J E VasquezF A Sarubbi
Oct 9, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kepler A DavisDuane R Hospenthal
Mar 8, 2006·Annals of Internal Medicine·Philip L GrahamElaine L Larson
Dec 11, 2007·American Journal of Infection Control·Jane D SiegelUNKNOWN Health Care Infection Control Practices Advisory Committee
Jan 18, 2008·PLoS Medicine·Heiman F L WertheimAlex van Belkum
Apr 22, 2008·The Journal of Infectious Diseases·Rachel J GorwitzMatthew J Kuehnert
May 13, 2008·The Lancet Infectious Diseases·Werner C Albrich, Stephan Harbarth
Nov 18, 2008·International Dental Journal·Abdulrohman AlNegrishFawwaz Al Sharafat
Jan 9, 2009·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Sun Hee ParkWan-Shik Shin
Mar 12, 2011·The Journal of Antimicrobial Chemotherapy·Jae-Hoon SongUNKNOWN ANSORP Study Group
Apr 5, 2011·American Journal of Infection Control·Alba N Apolonio-AlonsoAída Hamdan-Partida
Oct 4, 2011·American Journal of Infection Control·Marilyn C RobertsPeter Milgrom
Oct 21, 2011·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Stefano Petti, Antonella Polimeni
Feb 3, 2012·The Journal of the American Dental Association·Denise A Trochesset, Stephen G Walker
Feb 20, 2014·The Journal of Hospital Infection·F J Martínez-RuízA E Acosta-Gío

❮ Previous
Next ❯

Citations

Feb 27, 2019·Journal of Prevention & Intervention in the Community·William D Kernan
Jan 8, 2020·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Abiola SenokRalf Ehricht
Dec 14, 2018·Current Oral Health Reports·C M C Volgenant, J J de Soet
Aug 10, 2021·International Journal of Medical Microbiology : IJMM·Nadine LercheAxel Kramer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.